You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Kisunla ™ (donanemab-azbt) injection, for intravenous infusion
350 mg/20 mL (17.5 mg/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How should Kisunla® (donanemab-azbt) be administered?
Donanemab is administered as an intravenous infusion over approximately 30 minutes.
See important safety information, including boxed warning, in the attached prescribing information.
Administration Instructions
Prior to infusion,
- allow the donanemab diluted solution to warm to room temperature, and
- visually inspect the donanemab diluted solution for particles or discoloration.1
Do not use if it is discolored, or opaque or foreign particles are seen.1
Administer the entire diluted solution intravenously over approximately 30 minutes.1
Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity-type reaction and initiate appropriate treatment.1 The Infusion-Related Reactions and Hypersensitivity Reactions sections provide further information.
Flush the line only with 0.9% Sodium Chloride Injection at the end of infusion per access-specific line maintenance protocol.1
Observe the patient postinfusion for a minimum of 30 minutes to evaluate for infusion reactions and hypersensitivity reactions.1
Infusion-Related Reactions
Infusion-related reactions (IRRs) and hypersensitivity reactions have occurred in participants who were treated with donanemab.1
The majority of IRRs in the phase 3 TRAILBLAZER-ALZ 2 study
In some patients, infusion reactions and hypersensitivity reactions were reported more than 24 hours after a donanemab infusion.2
Signs and symptoms of IRRs include
- chills
- erythema
- nausea/vomiting
- flushing
- difficulty breathing/dyspnea
- sweating
- elevated blood pressure
- headache
- chest pain, and
- low blood pressure.1
Hypersensitivity Reactions
Donanemab is contraindicated in patients with a history of serious hypersensitivity to donanemab or to any of the excipients.1
Hypersensitivity reactions, including anaphylaxis and angioedema, have occurred in patients who were treated with donanemab.1
The infusion rate may be reduced, or the infusion may be discontinued, upon the first observation of any signs or symptoms consistent with infusion or hypersensitivity reactions, and appropriate therapy should be initiated.1
Enclosed Prescribing Information
References
1Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: May 04, 2026